Truvestments Capital LLC Invests $447,000 in Charles River Laboratories International, Inc. (NYSE:CRL)

Truvestments Capital LLC purchased a new stake in Charles River Laboratories International, Inc. (NYSE:CRL) in the first quarter, Holdings Channel.com reports. The institutional investor purchased 1,648 shares of the medical research company’s stock, valued at approximately $447,000.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Headlands Technologies LLC acquired a new position in Charles River Laboratories International in the first quarter valued at approximately $41,000. VisionPoint Advisory Group LLC boosted its holdings in Charles River Laboratories International by 45.1% in the fourth quarter. VisionPoint Advisory Group LLC now owns 209 shares of the medical research company’s stock valued at $49,000 after purchasing an additional 65 shares in the last quarter. Brown Brothers Harriman & Co. lifted its stake in Charles River Laboratories International by 76.0% in the fourth quarter. Brown Brothers Harriman & Co. now owns 220 shares of the medical research company’s stock valued at $52,000 after buying an additional 95 shares during the last quarter. GAMMA Investing LLC purchased a new stake in Charles River Laboratories International in the fourth quarter valued at approximately $62,000. Finally, Concord Wealth Partners lifted its stake in Charles River Laboratories International by 362.5% in the first quarter. Concord Wealth Partners now owns 259 shares of the medical research company’s stock valued at $70,000 after buying an additional 203 shares during the last quarter. 98.91% of the stock is owned by institutional investors and hedge funds.

Charles River Laboratories International Price Performance

NYSE:CRL traded up $11.66 during trading hours on Friday, hitting $233.47. The company’s stock had a trading volume of 646,236 shares, compared to its average volume of 451,382. The business’s 50-day moving average is $212.96 and its two-hundred day moving average is $230.20. The company has a market capitalization of $12.03 billion, a PE ratio of 27.47, a PEG ratio of 2.12 and a beta of 1.38. The company has a debt-to-equity ratio of 0.73, a quick ratio of 1.37 and a current ratio of 1.75. Charles River Laboratories International, Inc. has a 52-week low of $161.65 and a 52-week high of $275.00.

Charles River Laboratories International (NYSE:CRL) last released its quarterly earnings data on Thursday, May 9th. The medical research company reported $2.27 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.05 by $0.22. The firm had revenue of $1.01 billion during the quarter, compared to analysts’ expectations of $997.24 million. Charles River Laboratories International had a return on equity of 15.16% and a net margin of 10.81%. As a group, research analysts anticipate that Charles River Laboratories International, Inc. will post 10.99 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts have weighed in on CRL shares. TD Cowen reduced their price objective on Charles River Laboratories International from $260.00 to $228.00 and set a “hold” rating for the company in a research note on Monday, May 13th. StockNews.com cut Charles River Laboratories International from a “buy” rating to a “hold” rating in a research note on Friday, June 14th. Barclays started coverage on Charles River Laboratories International in a research note on Friday, June 28th. They issued an “equal weight” rating and a $230.00 price objective for the company. The Goldman Sachs Group initiated coverage on Charles River Laboratories International in a research note on Thursday, June 6th. They issued a “buy” rating and a $290.00 price objective for the company. Finally, Argus restated a “hold” rating on shares of Charles River Laboratories International in a research note on Friday, June 28th. Eight research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $252.29.

Insiders Place Their Bets

In other Charles River Laboratories International news, EVP Joseph W. Laplume sold 1,304 shares of the company’s stock in a transaction on Friday, May 10th. The stock was sold at an average price of $226.97, for a total value of $295,968.88. Following the sale, the executive vice president now owns 23,276 shares of the company’s stock, valued at $5,282,953.72. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 1.30% of the stock is currently owned by company insiders.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).